Amicus Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amicus Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About FOLD

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. 

CEO
Bradley Lewis Campbell
CEOBradley Lewis Campbell
Employees
511
Employees511
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
2002
Founded2002
Employees
511
Employees511

FOLD Key Statistics

Market cap
4.50B
Market cap4.50B
Price-Earnings ratio
-161.74
Price-Earnings ratio-161.74
Dividend yield
Dividend yield
Average volume
3.76M
Average volume3.76M
High today
$14.36
High today$14.36
Low today
$14.33
Low today$14.33
Open price
$14.35
Open price$14.35
Volume
5.57M
Volume5.57M
52 Week high
$14.38
52 Week high$14.38
52 Week low
$5.51
52 Week low$5.51

Stock Snapshot

As of today, Amicus Therapeutics(FOLD) shares are valued at $14.33. The company's market cap stands at 4.5B, with a P/E ratio of -161.74.

On 2026-03-04, Amicus Therapeutics(FOLD) stock moved within a range of $14.33 to $14.36. With shares now at $14.33, the stock is trading 0.0% above its intraday low and -0.2% below the session's peak.

Trading activity shows a volume of 5.57M, compared to an average daily volume of 3.76M.

Over the past 52 weeks, Amicus Therapeutics(FOLD) stock has traded between a high of $14.38 and a low of $5.51.

Over the past 52 weeks, Amicus Therapeutics(FOLD) stock has traded between a high of $14.38 and a low of $5.51.

FOLD News

Simply Wall St 19h
Is It Too Late To Consider Amicus Therapeutics After The Proposed BioMarin Deal Price?

If you are wondering whether Amicus Therapeutics at around US$14.34 is still attractively priced or already baking in a lot of optimism, you are in the right pl...

Is It Too Late To Consider Amicus Therapeutics After The Proposed BioMarin Deal Price?
TipRanks 1d
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting

Amicus ( (FOLD) ) just unveiled an announcement. On March 3, 2026, stockholders of Amicus Therapeutics approved the company’s acquisition by BioMarin Pharmaceu...

Analyst ratings

100%

of 7 ratings
Buy
0%
Hold
100%
Sell
0%

People also own

Based on the portfolios of people who own FOLD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.